RS62007B1 - Postupci pojačavanja tonične inhibicije i lečenja angelmanovog sindroma - Google Patents

Postupci pojačavanja tonične inhibicije i lečenja angelmanovog sindroma

Info

Publication number
RS62007B1
RS62007B1 RS20210718A RSP20210718A RS62007B1 RS 62007 B1 RS62007 B1 RS 62007B1 RS 20210718 A RS20210718 A RS 20210718A RS P20210718 A RSP20210718 A RS P20210718A RS 62007 B1 RS62007 B1 RS 62007B1
Authority
RS
Serbia
Prior art keywords
composition
drug
thip
use according
pharmaceutically acceptable
Prior art date
Application number
RS20210718A
Other languages
English (en)
Serbian (sr)
Inventor
Matthew During
Original Assignee
Ovid Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovid Therapeutics Inc filed Critical Ovid Therapeutics Inc
Publication of RS62007B1 publication Critical patent/RS62007B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
RS20210718A 2014-06-06 2015-06-03 Postupci pojačavanja tonične inhibicije i lečenja angelmanovog sindroma RS62007B1 (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462008939P 2014-06-06 2014-06-06
EP18169211.2A EP3372229B1 (en) 2014-06-06 2015-06-03 Methods of increasing tonic inhibition and treating angelman syndrome

Publications (1)

Publication Number Publication Date
RS62007B1 true RS62007B1 (sr) 2021-07-30

Family

ID=54767324

Family Applications (2)

Application Number Title Priority Date Filing Date
RS20210711A RS62006B1 (sr) 2014-06-06 2015-06-03 Postupci pojačavanja tonične inhibicije i lečenja sekundarne nesanice
RS20210718A RS62007B1 (sr) 2014-06-06 2015-06-03 Postupci pojačavanja tonične inhibicije i lečenja angelmanovog sindroma

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RS20210711A RS62006B1 (sr) 2014-06-06 2015-06-03 Postupci pojačavanja tonične inhibicije i lečenja sekundarne nesanice

Country Status (20)

Country Link
US (11) US20150352085A1 (enExample)
EP (3) EP3795156A1 (enExample)
JP (4) JP2017516868A (enExample)
AR (1) AR100772A1 (enExample)
AU (4) AU2015269667B2 (enExample)
CA (1) CA2950845C (enExample)
CY (2) CY1124368T1 (enExample)
DK (2) DK3372229T3 (enExample)
ES (2) ES2875742T3 (enExample)
HR (2) HRP20210901T1 (enExample)
HU (2) HUE055400T2 (enExample)
IL (2) IL249287B (enExample)
LT (2) LT3151832T (enExample)
MX (2) MX380868B (enExample)
PL (2) PL3151832T3 (enExample)
PT (2) PT3151832T (enExample)
RS (2) RS62006B1 (enExample)
SI (2) SI3372229T1 (enExample)
SM (2) SMT202100343T1 (enExample)
WO (1) WO2015187851A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS62006B1 (sr) 2014-06-06 2021-07-30 Ovid Therapeutics Inc Postupci pojačavanja tonične inhibicije i lečenja sekundarne nesanice
US10080898B2 (en) 2015-05-29 2018-09-25 Medtronic, Inc. Simultaneous physiological sensing and stimulation with saturation detection
US10434308B2 (en) 2015-05-29 2019-10-08 Medtronic, Inc. Impedance matching and electrode conditioning in patient interface systems
US9682069B2 (en) 2015-07-17 2017-06-20 Ovid Therapeutics Inc Methods of treating Dravet syndrome
MX391708B (es) 2015-07-17 2025-03-21 Ovid Therapeutics Inc Metodos para tratar trastornos del desarrollo con gaboxadol.
WO2018017639A1 (en) * 2016-07-19 2018-01-25 Georgia State University Research Foundation Methods for treating rett syndrome
KR102518846B1 (ko) 2016-08-11 2023-04-05 오비드 테라퓨틱스 인크. 간질 장애의 치료를 위한 방법 및 조성물
JP2019535760A (ja) * 2016-11-22 2019-12-12 オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． フルピルチンを用いた発達障害および／または発作性障害の処置方法
US10071083B2 (en) * 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
US20180338959A1 (en) * 2017-05-24 2018-11-29 Ovid Therapeutics Inc. Treatment of depressive disorders
EP3648762A4 (en) 2017-08-04 2021-03-24 Ovid Therapeutics, Inc. USE OF GABOXADOL IN THE TREATMENT OF DIABETES AND RELATED DISEASES
US11181384B2 (en) * 2018-07-23 2021-11-23 Waymo Llc Verifying map data using challenge questions
EP3833351A4 (en) * 2018-09-20 2021-10-13 Ovid Therapeutics Inc. USE OF GABOXADOL FOR THE TREATMENT OF GILLES DE LA TOURETTE SYNDROME, TICS AND STATTING
BR112021009944A2 (pt) * 2018-11-21 2021-08-17 Certego Therapeutics Inc. gaboxadol para reduzir risco de suicídio e alívio rápido de depressão
KR20210105387A (ko) 2018-12-17 2021-08-26 오비드 테라퓨틱스 인크. 비-24 시간 수면-각성 장애의 치료를 위한 가복사돌의 사용
US11786694B2 (en) 2019-05-24 2023-10-17 NeuroLight, Inc. Device, method, and app for facilitating sleep
CA3146737A1 (en) * 2019-07-15 2021-01-21 Ovid Therapeutics Inc. Pharmaceutical formulations containing gaboxadol for therapeutic treatment
AU2020405060A1 (en) * 2019-12-18 2022-06-09 Ovid Therapeutics Inc. Gaboxadol for therapeutic treatment of 1p36 deletion syndrome
JP2023526439A (ja) 2020-05-20 2023-06-21 セルテゴ セラピューティクス インコーポレイテッド 精神障害の処置のための環重水素化ガボキサドールおよびその使用
JP7600661B2 (ja) * 2020-12-11 2024-12-17 ａｒｔｉｅｎｃｅ株式会社 貼付剤
AU2024220869A1 (en) * 2023-02-17 2025-09-04 Ovid Therapeutics Inc. Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid in the treatment of multiple sclerosis

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK270378A (da) 1977-06-20 1978-12-21 Krogsgaard Larsen P Isoxazolderivater
US4362731A (en) 1980-09-01 1982-12-07 Sandoz Ltd. Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
US4353910A (en) 1981-11-27 1982-10-12 Kefalas A/S Derivatives of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridine-3-one, pharmaceutical compositions and methods of treatment
DE19525598C2 (de) * 1995-07-13 1997-09-25 Max Planck Gesellschaft Schlafmittel
DE19526864A1 (de) 1995-07-22 1997-01-23 Labtec Gmbh Hormonpflaster
US6461644B1 (en) 1996-03-25 2002-10-08 Richard R. Jackson Anesthetizing plastics, drug delivery plastics, and related medical products, systems and methods
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
US6676961B1 (en) 2002-03-06 2004-01-13 Automated Carrier Technologies, Inc. Transdermal patch assembly
US20050137222A1 (en) * 2003-12-18 2005-06-23 H. Lundbeck A/S Treatment of insomnia in human patients
AU2005229493A1 (en) 2004-04-02 2005-10-13 H. Lundbeck A/S Treatment of impaired respiratory function with gaboxadol
DE102005020882A1 (de) * 2005-05-04 2006-11-09 Dömling, Alexander, Dr. Verwendung von Gaboxadol und Derivaten zur Behandlung von Kinase-induzierten Krankheiten
US20110046090A1 (en) * 2005-10-31 2011-02-24 Braincells Inc. Modulation of neurogenesis with gaba agents and gaba analogs
US20090143335A1 (en) 2007-10-29 2009-06-04 H. Lundbeck A/S Modified absorption formulation of gaboxadol
WO2009064928A1 (en) 2007-11-13 2009-05-22 Cadence Pharmaceuticals Reduced dose intravenous acetaminophen
EP2334299A1 (en) * 2008-09-01 2011-06-22 H. Lundbeck A/S Pharmaceutical composition comprising gaboxadol and an inhibitor of patl or oat
RS62006B1 (sr) * 2014-06-06 2021-07-30 Ovid Therapeutics Inc Postupci pojačavanja tonične inhibicije i lečenja sekundarne nesanice
MX391708B (es) * 2015-07-17 2025-03-21 Ovid Therapeutics Inc Metodos para tratar trastornos del desarrollo con gaboxadol.
US9399034B1 (en) 2015-08-11 2016-07-26 Ovid Therapeutics Inc Methods of sedation during critical care treatment

Also Published As

Publication number Publication date
SMT202100340T1 (it) 2021-07-12
DK3372229T3 (da) 2021-06-14
ES2875742T3 (es) 2021-11-11
US20180303805A1 (en) 2018-10-25
MX380868B (es) 2025-03-12
SMT202100343T1 (it) 2021-07-12
HRP20210902T1 (hr) 2021-09-17
EP3151832A4 (en) 2018-01-17
PT3372229T (pt) 2021-06-17
CA2950845A1 (en) 2015-12-10
HUE055155T2 (hu) 2021-11-29
US20170071917A1 (en) 2017-03-16
AU2020217342A1 (en) 2020-08-27
US9801864B2 (en) 2017-10-31
US11278529B2 (en) 2022-03-22
US20220016091A1 (en) 2022-01-20
SI3372229T1 (sl) 2021-09-30
US20170087133A1 (en) 2017-03-30
US9446028B2 (en) 2016-09-20
JP2017516868A (ja) 2017-06-22
US20250025448A1 (en) 2025-01-23
PL3372229T3 (pl) 2021-10-04
US20170273956A1 (en) 2017-09-28
JP2021178836A (ja) 2021-11-18
PL3151832T3 (pl) 2021-10-25
US9339495B2 (en) 2016-05-17
AU2024202604A1 (en) 2024-05-09
US20150352085A1 (en) 2015-12-10
US20180015076A1 (en) 2018-01-18
EP3372229A1 (en) 2018-09-12
EP3795156A1 (en) 2021-03-24
JP2020063264A (ja) 2020-04-23
AR100772A1 (es) 2016-11-02
LT3372229T (lt) 2021-07-12
EP3151832B1 (en) 2021-03-24
US20230051859A1 (en) 2023-02-16
CY1124368T1 (el) 2022-07-22
AU2015269667A1 (en) 2016-12-22
SI3151832T1 (sl) 2021-08-31
MX391502B (es) 2025-03-21
IL268960B (en) 2021-05-31
CY1124366T1 (el) 2022-07-22
MX2016016136A (es) 2017-07-05
HUE055400T2 (hu) 2021-11-29
PT3151832T (pt) 2021-06-15
AU2022200085A1 (en) 2022-02-03
US9744159B2 (en) 2017-08-29
CA2950845C (en) 2023-04-25
DK3151832T3 (da) 2021-06-14
RS62006B1 (sr) 2021-07-30
LT3151832T (lt) 2021-07-12
US20160228418A1 (en) 2016-08-11
ES2876350T3 (es) 2021-11-12
IL249287B (en) 2021-03-25
AU2020217342B2 (en) 2021-10-07
EP3372229B1 (en) 2021-03-24
JP2023123442A (ja) 2023-09-05
WO2015187851A1 (en) 2015-12-10
EP3151832A1 (en) 2017-04-12
IL249287A0 (en) 2017-02-28
MX2020012404A (es) 2022-04-11
US20160038469A1 (en) 2016-02-11
IL268960A (en) 2019-10-31
AU2015269667B2 (en) 2020-07-30
HRP20210901T1 (hr) 2021-09-17

Similar Documents

Publication Publication Date Title
RS62007B1 (sr) Postupci pojačavanja tonične inhibicije i lečenja angelmanovog sindroma
US20250064783A1 (en) Compositions of Matter and Pharmaceutical Compositions
CN101600417B (zh) 用于神经递质的经鼻施用的控制释放递送系统
CN114040767A (zh) 用于治疗心理、认知、行为和/或情绪障碍的包含5ht受体激动剂的方法和组合物
JP2023076465A (ja) デクスメデトミジン製剤を使用する睡眠障害の予防または治療
MX2011004816A (es) Formulaciones de liberacion prolongada que comprenden un derivado de 2-oxo-1-pirrolidina.
CN111918646A (zh) 延迟释放去铁酮片剂及其使用方法
MX2011004572A (es) Formulaciones de liberacion prolongada que comprenden un derivado de 2-oxo-1-pirrolidina.
AU2024275806A1 (en) Formulations containing tryptamine derivatives and uses thereof
HK1260775B (en) Methods of increasing tonic inhibition and treating angelman syndrome
HK1260775A1 (en) Methods of increasing tonic inhibition and treating angelman syndrome
CN117120059A (zh) 胆钙化醇作为辅药在治疗肌营养不良中的用途
US11858908B2 (en) Compositions and methods for inhibiting IDO1
JP2003512311A (ja) Ｃｎｓ介在性障害を治療するための持続放出製剤